Skip to Content

'
Cathy Eng, M.D., FACP

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1994 Hahnemann University School of Medicine, Philadelphia, PA, MD, Doctorate of Medicine
1990 New York University, New York, NY, BA, Psychobiology and International Politics (Minor)

Selected Publications

Abstracts

1. Eng C, Van Cutsem E, Nowara E, Swieboda-Sadlej A, Tebbutt TC, Mitchell EP, Davidenko I, Oliner K, Chen L, Huang J, McCaffery I, Loh E, Smethurt D, Tabernero J. A Randomized, phase I/II trial of AMG 102 or AMG 479 in combination with panitumumab (pmab) compared with pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses. ASCO, Clinical Science Symposium 2011, 1/2011.
2. Jiang Z, Mehta TR, You YN, Chang GJ, Eng C, Overman MJ, Maru D, Hamilton SR, Kopetz S. Association of PTEN loss and local recurrence in stage II-III colon cancer. 2011 Gastrointestinal Cancer Symposium, 1/2011.
3. Lieu CH, Tran HT, Fiorentino S, Jiang Z, Mao M, Overman MJ, Eng C, Ellis LM, Heymach J, Kopetz S. Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer. 2011 Gastrointestinal Cancer Symposium, 1/2011.
4. Eng C, Xing Y, You YN, Chang JC, Phillips J, Wolff RA, Rodriguez-Bigas MA, Ohinata A, Crane CH. Cisplatin (C) based chemoradiation (CXRT) for locally advanced squamous cell carcinoma (SCCA) of the anal canal (AC): A 20-year perspective. 2011 Gastrointestinal Cancer Symposium, 1/2011.
5. Dawood SS, Gonzalez-Angulo AM, Eng C. Prognostic impact of baseline CEA level and surgery of primary tumor among patients with stage IV denovo colon cancer. 2011 Gastrointestinal Cancer Symposium, 1/2011.
6. Hassabo H, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett CR. Retrospective evaluation of patients with colorectal cancer (CRC) and type II non-insulin-dependent diabetes (NIDDM). 2011 Gastrointestinal Cancer Symposium, 1/2011.
7. Eng C, Bendell JC, Bessudo A, Gabrail NY, Diamon J, Pande AU, Gorbatchevsky I. Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-Met inhibitor, ARQ 1977, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy. 2011 Gastrointestinal Cancer Symposium, 1/2011.
8. Goerge B, You Y, Viswanathan C, Wen S, Baladandayuthapani V, Overman MJ, Kee BK, Kopetz S, Eng C, Garrett CR. Survival advantage associated with palliative oophorectomy in patients with metastatic colorectal cancer (CRC) to the ovaries (mCRC-O): A single institution retrospective analysis. 2011 Gastrointestinal Cancer Symposium, 1/2011.
9. Wang XS, Eng C, Fogelman DR, Malekifar M, Liao KE, Glover KY, Cleeland CS. Self-report neuropathy from oxaliplatin-based regimens in the treatment of colorectal cancer: With or without bevacizumab. 2011 Gastrointestinal Cancer Symposium, 1/2011.

Grant & Contract Support

Title: A randomized, placebo-controlled, Phase 1/2 Study of ARQ197 in combination with Irinotecan and Cetuximab in subjects with metastatic colorectal cancer with Wild-Type KRAS who have received front-line systemic therapy
Funding Source: Daiichi Pharmaceutical Corporation
Role: Principal Investigator
Duration: 4/8/2010 - 5/31/2013
 
Title: Biobehavioral Effects of Qigong During Rectal Cancer Treatment
Funding Source: NIH R21 2007-0825
Role: Co-Investigator
Principal Investigator: Lorenzo Cohen, M.D.
Duration: 3/1/2009 - present
 
Title: Retrospective tissue proteomics analysis of high-risk stage II and stage III colon cancer.
Funding Source: Urbieta Family Colon Cancer Research Fund
Role: Principal Investigator
Duration: 1/1/2006 - 12/31/2011
 
Title: Prognostic molecular and environmental markers in high-risk stage II/III colon cancer
Funding Source: Urbieta Family Colon Cancer Research Fund
Role: Principal Investigator
Duration: 1/1/2006 - 12/31/2011
 
Title: A Phase II Study of Capecitabine (Xeloda) / Oxaliplatin (Eloxatin) with Concomitant Radiotherapy (XRT), Xelox-XRT, in Squmous Cell Carcinoma of the Anal Canal
Funding Source: Sanofi Pharmaceuticals
Role: Principal Investigator-MDACC
Duration: 9/2004 - 4/2009
 
Title: U10 Full Member Application Affiliated with SWOG
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 7/26/2004 - 12/31/2015

Last updated: 8/27/2013